Traws Pharma (NASDAQ:TRAW) Trading Up 2.5% – Time to Buy?

Traws Pharma, Inc. (NASDAQ:TRAW) shares shot up 2.5% during mid-day trading on Thursday . The company traded as high as $2.69 and last traded at $2.49. 208,866 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 310,677 shares. The stock had previously closed at $2.43.

Analyst Ratings Changes

A number of brokerages have recently weighed in on TRAW. Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a report on Monday, December 22nd. HC Wainwright assumed coverage on Traws Pharma in a research note on Wednesday, December 3rd. They set a “buy” rating and a $8.00 target price on the stock. Zacks Research upgraded Traws Pharma to a “hold” rating in a report on Thursday, December 4th. Finally, Wall Street Zen lowered shares of Traws Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Traws Pharma Price Performance

The business has a 50 day simple moving average of $1.88 and a 200 day simple moving average of $1.91. The stock has a market cap of $19.90 million, a PE ratio of 0.03 and a beta of 1.66.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($9.16) by $8.82. Traws Pharma had a negative return on equity of 2,883.04% and a net margin of 3,028.25%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Traws Pharma stock. Two Sigma Investments LP grew its holdings in shares of Traws Pharma, Inc. (NASDAQ:TRAW) by 37.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,018 shares of the company’s stock after purchasing an additional 5,955 shares during the quarter. Two Sigma Investments LP owned about 0.31% of Traws Pharma worth $41,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.